SpletEligibility Checklist v2/28/2024 Page __ of __ Template -– Include all inclusion and exclusion criteria directly from the IRB approved study protocol. ELIGIBILITY CRITERIA – Maintain all supporting documentation for each answer and this document should be retained in the subject’s research file. SpletThis site uses cookies and other tracking technologies to assist with navigation, providing feedback, analyzing your use of our products and services, assisting with our promotional and marketing efforts, and provide content from third parties.
Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
SpletTROMBOLISIS EV 8: Administrar rtPA [Actylise]: dosis total: 0,9 mg/kg [dosis máxima 90 mg]; dividiéndola en 10% en bolo EV a pasar en 2 minutos y el resto a pasar en perfusión SpletΔ Patients who have a persistent neurologic deficit that is potentially disabling, despite … edry gitaris
Trombolisis en el Ictus Isquemico
SpletINCLUSION Is the subject: 1. Male or female aged 18-50 2. Capable of providing informed consent EXCLUSION Is the subject/does the subject have any of the following: 1. Current psychiatric diagnosis 2. Lifetime psychiatric diagnosis with the exception of major depressive disorder & anxiety disorders (if not within the past 12 months) 3. SpletTable 1: TTM Inclusion and Exclusion Criteria Inclusion Criteria Remains comatose immediately following out -of hospital or in hospital cardiac arrest with return of spontaneous circulation, regardless of initial cardiac rhythm Exclusion Criteria GCS (motor) = 6 and patient following commands Splet14. apr. 2024 · 0.9mg/kg alteplase (r-TPA) (maximum 90mg) over 60 minutes (10% given as a bolus) INDICATIONS. Consider for acute ischaemic CVA within 3 hours of onset after exclusion of haemorrhage; Most appropriately used in a stroke center or as part of a randomised controlled trial; Used up to 4.5 hours in some centers based on ECASS-III constellis contact information